Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
November 08 2017 - 9:00AM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will present at the Jefferies 2017 London Healthcare
Conference on November 15, 2017 at 2:00 p.m. GMT (9:00 a.m. EST).
The presentation will be web cast and accessible through the
investor relations section of the Company’s web site,
http://ir.minervaneurosciences.com.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and major
depressive disorder (MDD); MIN-117, in clinical development for
MDD; and MIN-301, in pre-clinical development for Parkinson’s
disease. Minerva’s common stock is listed on the NASDAQ
Global Market under the symbol “NERV.” For more information,
please visit www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024